Fluoptics raises €2 million for global business development

Fluoptics raised €2 million from business angels in September, which it will use to market its Fluobeam® system for several clinical applications in the United States, Asia, and Europe. The Fluobeam® fluorescence imaging system already has the CE marking for medical devices and should get FDA approval in early 2014; approval is pending in several Asian countries.
Fluobeam® is already in use at 25 research centers in seven countries. The company is targeting a global market of 66,000 hospitals and clinics for use in cardiovascular, reconstructive, cancer, and liver surgery. It plans to soon hire four new employees. For now Fluoptics’ international sales expansion will be driven by its distribution network.
 

Contact: odile.allard@fluoptics.com

Facebook

Twitter